FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo (Dec. 27)
By Sneha S K and Sriparna Roy (Reuters) -The U.S. Food and Drug Administration said on Friday that it has approved an ...
MarketWatch13d
Bristol Myers Squibb Receives FDA Approval for Cancer Treatment
Bristol Myers Squibb received approval from the Food and Drug Administration ... who directs network clinical trials at Roswell Park Comprehensive Cancer Center. This quicker delivery may allow ...
MedCity News11d
Bristol Myers Squibb Wins FDA Nod for Injectable Version of Blockbuster Cancer Drug
Bristol Myers Squibb has won FDA approval for an injectable version of its blockbuster cancer immunotherapy Opdivo, a regulatory decision that gives patients a more convenient dosing option and ...
FiercePharma8d
Bristol Myers celebrates 10 years of Opdivo with FDA approval for subcutaneous version
Almost exactly 10 years after the FDA’s initial FDA approval for Bristol Myers Squibb’s Opdivo as the first PD-1 inhibitor in ...
Here's what Big Pharma could buy in 2025, from obesity drugs to precision cancer treatments, according to a top M&A banker
Jefferies investment banker Chris Roop discussed the Big Pharma M&A outlook with Business Insider. Check out the types of ...
International Assets Investment Management LLC Decreases Stake in Bristol-Myers Squibb (NYSE:BMY)
International Assets Investment Management LLC cut its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 98.4% ...
Pharmaceutical Technology5d
BMS-986484 by Bristol-Myers Squibb for Non-Small Cell Lung Cancer: Likelihood of Approval
BMS-986484 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Non-Small Cell Lung Cancer.
FiercePharma12h
2025 forecast: As companies rush to radiopharmaceuticals for oncology, what's next?
In the span of eight months, Big Pharma companies took over four of the hottest radiopharmaceutical players in the industry.
Bristol-Myers Squibb (NYSE:BMY) Position Increased by Legacy Private Trust Co.
Legacy Private Trust Co. lifted its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 3.3% during the 4th quarter, ...